PolTREG S.A., a company dedicated to commercializing breakthrough therapy for type 1 diabetes in children, has acquired two new equity investors: Venture VIZ from TRIGON TFI and a fund managed by PAAN Capital. Invest Concept acted as a transaction advisor for PolTREG.

PolTREG also received PLN 2 million from the Innovation Support Loan Fund of the Polish Agency for Enterprise Development. The capital raised will enable it to launch at the turn of 2017 and 2018 a laboratory that will increase the scale of therapeutic use.